155 related articles for article (PubMed ID: 15359659)
1. Effect of DCEP mobilizing regimen in in vivo purging of PBSC harvests in multiple myeloma.
Novella E; Madeo D; Albiero E; Roberti S; Castaman G; Elice F; Rodeghiero F
Leuk Lymphoma; 2004 Jul; 45(7):1497-9. PubMed ID: 15359659
[No Abstract] [Full Text] [Related]
2. DCEP (dexamethasone, cyclophosphamide, etoposide, and cisplatin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma.
Lazzarino M; Corso A; Barbarano L; Alessandrino EP; Cairoli R; Pinotti G; Ucci G; Uziel L; Rodeghiero F; Fava S; Ferrari D; Fiumanò M; Frigerio G; Isa L; Luraschi A; Montanara S; Morandi S; Perego D; Santagostino A; Savarè M; Vismara A; Morra E
Bone Marrow Transplant; 2001 Nov; 28(9):835-9. PubMed ID: 11781643
[TBL] [Abstract][Full Text] [Related]
3. A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agents.
Lerro KA; Medoff E; Wu Y; Seropian SE; Snyder E; Krause D; Cooper DL
Bone Marrow Transplant; 2003 Dec; 32(12):1113-7. PubMed ID: 14647264
[TBL] [Abstract][Full Text] [Related]
4. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma.
Popat U; Saliba R; Thandi R; Hosing C; Qazilbash M; Anderlini P; Shpall E; McMannis J; Körbling M; Alousi A; Andersson B; Nieto Y; Kebriaei P; Khouri I; de Lima M; Weber D; Thomas S; Wang M; Jones R; Champlin R; Giralt S
Biol Blood Marrow Transplant; 2009 Jun; 15(6):718-23. PubMed ID: 19450756
[TBL] [Abstract][Full Text] [Related]
5. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
[TBL] [Abstract][Full Text] [Related]
6. Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma.
Petrucci MT; Avvisati G; La Verde G; De Fabritiis P; Ribersani M; Palumbo G; De Felice L; Rusignuolo A; Simone F; Meloni G; Mandelli F
Acta Haematol; 2003; 109(4):184-8. PubMed ID: 12853690
[TBL] [Abstract][Full Text] [Related]
7. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma.
Arcaini L; Montanari F; Alessandrino EP; Tucci A; Brusamolino E; Gargantini L; Cairoli R; Bernasconi P; Passamonti F; Bonfichi M; Zoli V; Bottelli C; Calatroni S; Troletti D; Merli M; Pascutto C; Majolino I; Rossi G; Morra E; Lazzarino M
Ann Oncol; 2008 Jul; 19(7):1331-1335. PubMed ID: 18344536
[TBL] [Abstract][Full Text] [Related]
8. The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma.
Corso A; Barbarano L; Zappasodi P; Cairoli R; Alessandrino EP; Mangiacavalli S; Ferrari D; Fava S; Fiumanò M; Frigerio G; Isa L; Luraschi A; Klersy C; De Paoli A; Vergani C; Banfi L; Perego D; Ucci G; Pinotti G; Savarè M; Uziel L; Vismara A; Morra E; Lazzarino M
Haematologica; 2004 Sep; 89(9):1124-7. PubMed ID: 15377474
[TBL] [Abstract][Full Text] [Related]
9. Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study.
de la Rubia J; Bladé J; Lahuerta JJ; Ribera JM; Martínez R; Alegre A; García-Laraña J; Fernández P; Sureda A; de Arriba F; Carrera D; Besalduch J; García Boyero R; Palomera Bernal L; Hernández MT; García PR; Pérez-Calvo J; Alcalá A; Casado LF; San Miguel J
Haematologica; 2006 May; 91(5):621-7. PubMed ID: 16627253
[TBL] [Abstract][Full Text] [Related]
10. Blood stem cell collection using chemotherapy with or without systematic G-CSF: experience in 52 patients with multiple myeloma.
Lefrere F; Makke J; Fermand J; Marolleau J; Dal Cortivo L; Alberti C; Mouton V; Benbunan M; Miclea J
Bone Marrow Transplant; 1999 Sep; 24(5):463-6. PubMed ID: 10482928
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide plus etoposide is a safe and effective mobilization regimen in patients with multiple myeloma.
Heider M; Grass S; Dill V; Rämisch S; Winter C; Verbeek M; Götze KS; Bassermann F; Jilg S
Transfus Apher Sci; 2021 Oct; 60(5):103197. PubMed ID: 34175195
[TBL] [Abstract][Full Text] [Related]
12. Treatment with hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate results in poor mobilization of peripheral blood stem cells in patients with mantle cell lymphoma.
Hill BT; Rybicki L; Smith S; Dean R; Kalaycio M; Pohlman B; Sweetenham J; Tench S; Sobecks R; Andresen S; Copelan E; Bolwell BJ
Leuk Lymphoma; 2011 Jun; 52(6):986-93. PubMed ID: 21314484
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, toxicity and feasibility of a shorter schedule of DCEP regimen for stem cell mobilization in multiple myeloma.
Corso A; Mangiacavalli S; Nosari A; Castagnola C; Zappasodi P; Cafro AM; Astori C; Bonfichi M; Varettoni M; Rusconi C; Troletti D; Pascutto C; Morra E; Lazzarino M;
Bone Marrow Transplant; 2005 Dec; 36(11):951-4. PubMed ID: 16184179
[TBL] [Abstract][Full Text] [Related]
14. Gene scanning of VDJH-amplified segments is a clinically relevant technique to detect contaminating tumor cells in the apheresis products of multiple myeloma patients undergoing autologous peripheral blood stem cell transplantation.
López-Pérez R; García-Sanz R; González D; Balanzategui A; Chillón MC; Alaejos I; Mateos MV; Caballero MD; Corral M; Orfão A; González M; San Miguel JF
Bone Marrow Transplant; 2001 Oct; 28(7):665-72. PubMed ID: 11704789
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow up of sequential mobilisation and autologous transplantation with CD34-selected cells in multiple myeloma: a multimodality approach.
Horvath N; Hahn U; Joshua D; Dyson P; Gibson J; Stevens J; Rawling T; Barrow L; Brown R; Stephens S; Gower G; Norman J; Mills B; To LB
Intern Med J; 2004 Apr; 34(4):167-75. PubMed ID: 15086696
[TBL] [Abstract][Full Text] [Related]
16. Modified CVAD and modified CBAD compared to high-dose cyclophosphamide for peripheral blood stem cell mobilization in patients with multiple myeloma.
Gettys SC; Gulbis A; Wilhelm K; Sasaki K; Dinh Y; Rondon G; Qazilbash MH
Eur J Haematol; 2017 Apr; 98(4):388-392. PubMed ID: 28009447
[TBL] [Abstract][Full Text] [Related]
17. A combination of dexamethasone, cyclophosphamide, etoposide, and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilization in multiple myeloma.
Corso A; Arcaini L; Caberlon S; Zappasodi P; Mangiacavalli S; Lorenzi A; Rusconi C; Troletti D; Maiocchi MA; Pascutto C; Morra E; Lazzarino M
Haematologica; 2002 Oct; 87(10):1041-5. PubMed ID: 12368158
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood stem cell collection in children with acute leukemia: effectiveness of the 'DIAVE' mobilizing regimen.
Balduzzi A; Perseghin P; Dassi M; Bonanomi S; Rovelli A; Gaipa G; Biondi A; Uderzo C
Bone Marrow Transplant; 2002 Oct; 30(7):413-6. PubMed ID: 12368951
[TBL] [Abstract][Full Text] [Related]
19. Collection of peripheral blood stem cells in new patients with myeloma receiving minimal or no prior cytoreductive therapy.
Sirohi B; Powles R; Cavanagh J; Oakervee H; Dyer P; Rintala T; Kulkarni S; Rudin C; Horton C; Treleaven J; Morgan G
Hematology; 2007 Apr; 12(2):113-5. PubMed ID: 17454191
[TBL] [Abstract][Full Text] [Related]
20. Retrospective comparison of mobilization methods for autologous stem cell transplantation in multiple myeloma.
Nakasone H; Kanda Y; Ueda T; Matsumoto K; Shimizu N; Minami J; Sakai R; Hagihara M; Yokota A; Oshima K; Tsukada Y; Tachibana T; Nakaseko C; Fujisawa S; Yano S; Fujita H; Takahashi S; Kanamori H; Okamoto S;
Am J Hematol; 2009 Dec; 84(12):809-14. PubMed ID: 19862826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
